Molecular monitoring of response to imatinib (Glivec®) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission
A significant proportion of chronic myeloid leukemia (CML) patients achieve a major cytogenetic remission (MCR) to imatinib therapy after failing interferon (IFN) α-based protocols. We sought to determine levels of residual disease in patients with MCR using various molecular methods and to establis...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
10 September 2003
|
| In: |
Leukemia
Year: 2003, Jahrgang: 17, Heft: 9, Pages: 1687-1694 |
| ISSN: | 1476-5551 |
| DOI: | 10.1038/sj.leu.2403033 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1038/sj.leu.2403033 Verlag, lizenzpflichtig, Volltext: https://www.nature.com/articles/2403033 
|
| Verfasserangaben: | P. Paschka, M.C. Müller, K. Merx, S. Kreil, C. Schoch, T. Lahaye, A. Weisser, A. Petzold, H. König, U. Berger, H. Gschaidmeier, R. Hehlmann and A. Hochhaus |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 180183556X | ||
| 003 | DE-627 | ||
| 005 | 20230426073534.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220516s2003 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/sj.leu.2403033 |2 doi | |
| 035 | |a (DE-627)180183556X | ||
| 035 | |a (DE-599)KXP180183556X | ||
| 035 | |a (OCoLC)1341459926 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Paschka, Peter |d 1970- |e VerfasserIn |0 (DE-588)123089840 |0 (DE-627)706156870 |0 (DE-576)293550832 |4 aut | |
| 245 | 1 | 0 | |a Molecular monitoring of response to imatinib (Glivec®) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission |c P. Paschka, M.C. Müller, K. Merx, S. Kreil, C. Schoch, T. Lahaye, A. Weisser, A. Petzold, H. König, U. Berger, H. Gschaidmeier, R. Hehlmann and A. Hochhaus |
| 264 | 1 | |c 10 September 2003 | |
| 300 | |a 8 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 16.05.2022 | ||
| 520 | |a A significant proportion of chronic myeloid leukemia (CML) patients achieve a major cytogenetic remission (MCR) to imatinib therapy after failing interferon (IFN) α-based protocols. We sought to determine levels of residual disease in patients with MCR using various molecular methods and to establish a relation between residual BCR-ABL transcript levels and rate of relapse in complete cytogenetic remission (CCR). Response was measured by conventional cytogenetic analysis, hypermetaphase and interphase fluorescence in situ hybridization (HM-FISH, IP-FISH) of bone marrow (BM) cells, qualitative nested and quantitative reverse transcriptase polymerase chain reaction (RT-PCR) for BCR-ABL transcripts. We investigated 323 peripheral blood (PB) and BM samples from 48 CML patients who achieved a complete (Ph+ 0%; n=41) or partial (Ph+ 1-34%; n=7) cytogenetic remission after 3-20 months of imatinib therapy. Prior to imatinib, 35 patients were in chronic phase (CP), eight in accelerated phase (AP), four in myeloid and one in lymphoid blast crisis. HM-FISH results correlated with ratios BCR-ABL/ABL in PB and BM. In patients with CCR, residual disease was detectable by HM-FISH (31%), IP-FISH (18%), and RT-PCR (100%). During follow-up, BCR-ABL became undetectable in two patients (one CP, one AP) by both nested and quantitative RT-PCR. CCR is ongoing in 30 evaluable patients, 11 patients have relapsed. At the time of best response, median ratios BCR-ABL/ABL were 2.1% (range 0.82-7.8) in patients with subsequent relapse and 0.075% (range 0-3.9) in patients with ongoing remission (P=0.0011). All 16 CP patients, who achieved ratios BCR-ABL/ABL <0.1% as best molecular response are in continuous remission, while 6/13 patients (46%) with ratios ⩾0.1% have relapsed (P=0.0036). We conclude that: (i) in patients with CCR to imatinib, HM-FISH and RT-PCR usually reveal residual BCR-ABL+ cells; (ii) RT-PCR results derived from PB and BM are comparable in CP CML; and (iii) low levels of residual disease with ratios BCR-ABL/ABL <0.1% are associated with continuous remission. | ||
| 650 | 4 | |a Cancer Research | |
| 650 | 4 | |a general | |
| 650 | 4 | |a Hematology | |
| 650 | 4 | |a Intensive / Critical Care Medicine | |
| 650 | 4 | |a Internal Medicine | |
| 650 | 4 | |a Medicine/Public Health | |
| 650 | 4 | |a Oncology | |
| 700 | 1 | |a Müller, Martin Christian |d 1972- |e VerfasserIn |0 (DE-588)121360296 |0 (DE-627)705409236 |0 (DE-576)181482819 |4 aut | |
| 700 | 1 | |a Merx, Kirsten |d 1970- |e VerfasserIn |0 (DE-588)122413091 |0 (DE-627)70589892X |0 (DE-576)293258910 |4 aut | |
| 700 | 1 | |a Kreil, Sebastian |d 1972- |e VerfasserIn |0 (DE-588)1072240564 |0 (DE-627)827077742 |0 (DE-576)433714093 |4 aut | |
| 700 | 1 | |a Schoch, C. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Lahaye, T. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Weißer, Andreas |d 1968- |e VerfasserIn |0 (DE-588)121859428 |0 (DE-627)705680622 |0 (DE-576)292922833 |4 aut | |
| 700 | 1 | |a Petzold, A. |e VerfasserIn |4 aut | |
| 700 | 1 | |a König, H. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Berger, Ute |e VerfasserIn |0 (DE-588)1255399929 |0 (DE-627)1799635341 |4 aut | |
| 700 | 1 | |a Gschaidmeier, Harald |d 1965- |e VerfasserIn |0 (DE-588)172811074 |0 (DE-627)697741354 |0 (DE-576)133667324 |4 aut | |
| 700 | 1 | |a Hehlmann, Rüdiger |d 1941- |e VerfasserIn |0 (DE-588)1037003489 |0 (DE-627)751737879 |0 (DE-576)390939463 |4 aut | |
| 700 | 1 | |a Hochhaus, Andreas |d 1959- |e VerfasserIn |0 (DE-588)1107039339 |0 (DE-627)863321976 |0 (DE-576)474976130 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Leukemia |d London : Springer Nature, 1997 |g 17(2003), 9, Seite 1687-1694 |h Online-Ressource |w (DE-627)32046699X |w (DE-600)2008023-2 |w (DE-576)094139733 |x 1476-5551 |7 nnas |a Molecular monitoring of response to imatinib (Glivec®) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission |
| 773 | 1 | 8 | |g volume:17 |g year:2003 |g number:9 |g pages:1687-1694 |g extent:8 |a Molecular monitoring of response to imatinib (Glivec®) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission |
| 856 | 4 | 0 | |u https://doi.org/10.1038/sj.leu.2403033 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://www.nature.com/articles/2403033 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20220516 | ||
| 993 | |a Article | ||
| 994 | |a 2003 | ||
| 998 | |g 1107039339 |a Hochhaus, Andreas |m 1107039339:Hochhaus, Andreas |d 60000 |d 61200 |e 60000PH1107039339 |e 61200PH1107039339 |k 0/60000/ |k 1/60000/61200/ |p 13 |y j | ||
| 998 | |g 1037003489 |a Hehlmann, Rüdiger |m 1037003489:Hehlmann, Rüdiger |d 60000 |d 61200 |e 60000PH1037003489 |e 61200PH1037003489 |k 0/60000/ |k 1/60000/61200/ |p 12 | ||
| 998 | |g 1255399929 |a Berger, Ute |m 1255399929:Berger, Ute |d 60000 |d 61200 |e 60000PB1255399929 |e 61200PB1255399929 |k 0/60000/ |k 1/60000/61200/ |p 10 | ||
| 998 | |g 121859428 |a Weißer, Andreas |m 121859428:Weißer, Andreas |d 60000 |d 61200 |e 60000PW121859428 |e 61200PW121859428 |k 0/60000/ |k 1/60000/61200/ |p 7 | ||
| 998 | |g 1072240564 |a Kreil, Sebastian |m 1072240564:Kreil, Sebastian |d 60000 |d 61200 |e 60000PK1072240564 |e 61200PK1072240564 |k 0/60000/ |k 1/60000/61200/ |p 4 | ||
| 998 | |g 122413091 |a Merx, Kirsten |m 122413091:Merx, Kirsten |d 60000 |d 61200 |e 60000PM122413091 |e 61200PM122413091 |k 0/60000/ |k 1/60000/61200/ |p 3 | ||
| 998 | |g 121360296 |a Müller, Martin Christian |m 121360296:Müller, Martin Christian |d 60000 |d 61200 |e 60000PM121360296 |e 61200PM121360296 |k 0/60000/ |k 1/60000/61200/ |p 2 | ||
| 998 | |g 123089840 |a Paschka, Peter |m 123089840:Paschka, Peter |d 60000 |d 61200 |e 60000PP123089840 |e 61200PP123089840 |k 0/60000/ |k 1/60000/61200/ |p 1 |x j | ||
| 999 | |a KXP-PPN180183556X |e 4134374324 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"id":{"doi":["10.1038/sj.leu.2403033"],"eki":["180183556X"]},"name":{"displayForm":["P. Paschka, M.C. Müller, K. Merx, S. Kreil, C. Schoch, T. Lahaye, A. Weisser, A. Petzold, H. König, U. Berger, H. Gschaidmeier, R. Hehlmann and A. Hochhaus"]},"physDesc":[{"extent":"8 S."}],"recId":"180183556X","relHost":[{"language":["eng"],"part":{"issue":"9","text":"17(2003), 9, Seite 1687-1694","pages":"1687-1694","year":"2003","extent":"8","volume":"17"},"physDesc":[{"extent":"Online-Ressource"}],"recId":"32046699X","id":{"issn":["1476-5551"],"zdb":["2008023-2"],"eki":["32046699X"]},"title":[{"title":"Leukemia","subtitle":"normal and malignant hemopoiesis ; a peer-reviewed journal","title_sort":"Leukemia"}],"pubHistory":["Nachgewiesen 11.1997 -"],"note":["Gesehen am 15.03.04"],"origin":[{"dateIssuedDisp":"1997-","publisher":"Springer Nature ; Stockton Press ; Nature Publ. Group","dateIssuedKey":"1997","publisherPlace":"London ; Basingstoke [u.a.] ; Basingstoke"}],"type":{"bibl":"periodical","media":"Online-Ressource"},"disp":"Molecular monitoring of response to imatinib (Glivec®) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remissionLeukemia"}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"note":["Gesehen am 16.05.2022"],"origin":[{"dateIssuedDisp":"10 September 2003","dateIssuedKey":"2003"}],"title":[{"title_sort":"Molecular monitoring of response to imatinib (Glivec®) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission","title":"Molecular monitoring of response to imatinib (Glivec®) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission"}],"language":["eng"],"person":[{"role":"aut","given":"Peter","display":"Paschka, Peter","family":"Paschka"},{"family":"Müller","display":"Müller, Martin Christian","role":"aut","given":"Martin Christian"},{"display":"Merx, Kirsten","family":"Merx","role":"aut","given":"Kirsten"},{"display":"Kreil, Sebastian","family":"Kreil","given":"Sebastian","role":"aut"},{"role":"aut","given":"C.","family":"Schoch","display":"Schoch, C."},{"family":"Lahaye","display":"Lahaye, T.","role":"aut","given":"T."},{"given":"Andreas","role":"aut","display":"Weißer, Andreas","family":"Weißer"},{"given":"A.","role":"aut","display":"Petzold, A.","family":"Petzold"},{"role":"aut","given":"H.","display":"König, H.","family":"König"},{"given":"Ute","role":"aut","display":"Berger, Ute","family":"Berger"},{"role":"aut","given":"Harald","family":"Gschaidmeier","display":"Gschaidmeier, Harald"},{"given":"Rüdiger","role":"aut","display":"Hehlmann, Rüdiger","family":"Hehlmann"},{"family":"Hochhaus","display":"Hochhaus, Andreas","role":"aut","given":"Andreas"}]} | ||
| SRT | |a PASCHKAPETMOLECULARM1020 | ||